



DOI: <https://doi.org/10.56936/18290825-2026.20v.1-67>

RELATIONSHIP BETWEEN SERUM TESTOSTERONE AND OSTEOPOROSIS IN OLDER MEN: A CROSS-SECTIONAL STUDY

ALAM A.R.¹, MUSTARI M.N.², LATIEF J.², RASJAD C.², BAUSAT A.²,
ZAINUDDIN A.A.³, PRIHANTONO P.¹, FARUK M.¹

¹. Department of Surgery, Faculty of Medicine, Hasanuddin University Makassar, Indonesia

². Division of Orthopedic and Traumatology Surgery, Department of Surgery, Faculty of Medicine, Hasanuddin University Makassar, Indonesia

³. Department of Public Health and Community Medicine Science, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Received 20.12.2024; Accepted for printing 14.05.2026

ABSTRACT

Introduction: Low testosterone levels in older men cause a decrease in bone mass density. Osteoporosis is divided into primary and secondary types: the former occurs without known risk factors, whereas risk factors have been identified for the latter. The causes of secondary osteoporosis in older men include hypogonadism (i.e., decreased levels of the hormone testosterone). The Singh index is an affordable and straightforward method of determining bone mass density at a fracture site. The current study investigated the relationship between serum testosterone levels and the severity of osteoporosis (according to the Singh index) in older men.

Materials and Methods: This cross-sectional study was conducted at Wahidin Sudirohusodo hospital, Makassar, Indonesia. with participants comprised of men aged greater than 50 years. The Singh index is divided into six grades ranging from 1 (severe osteoporosis) to 6 (normal bone density). Anteroposterior pelvic X-ray was conducted to determine bone density. Testosterone serum levels were examined by an ELISA method (enzyme-linked immunosorbent assay).

Results: The average testosterone level was 117.88 ± 110.22 ng/dL. The highest osteoporosis score was Singh index grade 3 (definitive osteoporosis), which was recorded for 14 patients (26%; $p < 0.001$). There was a significant correlation between serum testosterone levels and the severity of osteoporosis according to Singh index grade among older men (p -value < 0.001).

Conclusions: Decreased serum testosterone levels in elderly men were significantly related to the severity of osteoporosis according to the Singh index grade. The Singh index could therefore be a useful screening method for the assessment of osteoporosis.

KEYWORDS: cross-sectional study; osteoporosis; Singh index; testosterone.

INTRODUCTION

Osteoporosis is a major public-health issue worldwide [Sozen *et al.*, 2017]. While traditionally viewed primarily as a disease of postmenopausal

women, osteoporosis in men represents a growing, yet frequently underdiagnosed and undertreated, clinical challenge. Both men and women may begin to experience bone loss around the age of 50

CITE THIS ARTICLE AS:

ALAM A.R., MUSTARI M.N., LATIEF J., RASJAD C., BAUSAT A., ZAINUDDIN A.A., PRIHANTONO P., FARUK M. (2026). Relationship Between Serum Testosterone and Osteoporosis in Older Men: A cross-sectional study; The New Armenian Medical Journal, vol.20 (1), 67-73; DOI: <https://doi.org/10.56936/18290825-2026.20v.1-67>

ADDRESS FOR CORRESPONDENCE:

Muhammad Nasser Mustari, MD-PhD
Department of Surgery, Faculty of Medicine, Hasanuddin University Makassar, Indonesia
Jalan Perintis Kemerdekaan KM 11, Sulawesi Selatan, 90245, Makassar, Indonesia
Tel.: +62411585984
E-mail: mnassermustari1@gmail.com

years, and one in eight men aged >50 years will experience a fracture due to osteoporosis [Kaufman et al., 2013]. One-third of all hip fractures occur in older males, and these fractures are associated with higher morbidity and mortality rates compared to women, making this a severe clinical health problem. The risk of osteoporotic fracture among Caucasian men aged ≥ 60 years has been estimated as 21% in England and Wales, and as 15% in Australia for those aged ≥ 75 years [Sozen et al., 2017; Kaufman et al., 2013]. Despite these alarming statistics, male osteoporosis remains inadequately screened.

Osteoporosis is broadly divided into primary and secondary types [Foroutan, 2024]. Primary osteoporosis occurs without known secondary risk factors and is generally associated with age-related bone loss. In contrast, specific medical conditions or treatments cause secondary osteoporosis. The causes of secondary osteoporosis in older men are diverse and include hypogonadism (decreased testosterone levels), prolonged use of glucocorticoids, immunosuppressant drugs, anticonvulsants, excessive alcohol intake, smoking, hypocalcemia, hyperthyroidism, and hyperparathyroidism [Fink H. et al., 2006; Golds et al., 2017; Aggarwal W et al., 2023]. Among these, age-related decline in sex steroids is a critical but often overlooked factor.

Serum total testosterone reference ranges were based on harmonized values reported by Bhasin et al. and recommendations from the Endocrine Society, with normal adult male levels ranging from 9.2 to 31.8 nmol/L and age-related decline observed in elderly men (Table 1) [Bhasin et al., 2017].

Osteoporosis has been shown to be more prevalent among elderly men with severe testosterone deficiency. Conversely, deficiency of total testosterone or estradiol is more frequently detected in elderly men with osteoporosis [Fink H., 2006].

It has been reported that osteoporosis was noted in 39.3% of elderly men aged >60 years attending the outpatient department. Decreased serum testosterone levels were significantly associated with male osteoporosis, as measured by Bone Mineral Density (BMD). The association between testosterone levels and osteoporosis was statistically significant, with a p-value of 0.019 (Table 2) [Aggarwal V., 2023].

The reported prevalence of male osteoporosis

was high; therefore, it is important to develop a screening protocol for elderly men to diagnose osteoporosis early and prevent osteoporotic fractures where possible (Table 3) [Kanis et al., 2012; Watts, 2012; Bhasin, 2018; Camacho et al., 2020; Aggarwal et al., 2023].

Based on recommendations defining biochemical thresholds for testosterone deficiency in older men (200–300 ng/dL) [APTRM, 2001], participants were categorized as testosterone deficient (<200 ng/dL [6.9 nmol/L]), possibly testosterone deficient (200–400 ng/dL [6.9–13.9 nmol/L]), or normal (≥ 400 ng/dL [≥ 13.9 nmol/L]). Secondary analyses further stratified participants into subgroups: <200 ng/dL, 200–<300 ng/dL, 300–<400 ng/dL, 400–<500 ng/dL, and ≥ 500 ng/dL [Fink et al., 2006].

Low testosterone levels in older men can cause a significant decrease in bone mineral density. Sex steroid hormones play an essential role in regulating bone formation and bone mass in both men and women [Aggarwal et al., 2023]. Testosterone promotes bone health both directly, by binding to androgen receptors on osteoblasts and osteocytes to stimulate bone formation, and indirectly, through aromatization into estrogen, which inhibits bone resorption. A study in the United States found that decreased testosterone levels were associated with a 2.5-fold increase in the risk of non-vertebral fractures [Binkley et al., 2014; Golds et al., 2017]. Consequently, early identification of hypogonad-

TABLE 1.

Reference ranges of serum total testosterone in adult and elderly men

Age (years)	Testosterone (nmol/L)
20–39	9.2 – 31.8
40–49	8.6 – 29.0
50–59	7.6 – 27.0
60–69	6.7 – 25.7
≥ 70	5.4 – 24.6

TABLE 2.

Association between serum testosterone levels and osteoporosis in elderly men aged >60 years [Aggarwal, V 2023].

Testosterone levels	Osteoporosis		Total	p-value
	present	absent		
> 300 ng/dL	50	51	101	0.019
< 300 ng/dL	111	196	307	
Total	161	247	408	

TABLE 3.

Serum Total Testosterone Levels in Elderly Men According to the Degree of Osteoporosis and Singh Index Grades .					
Osteoporosis Grade		Bone Tissue Characteristics	Testosterone (nmol/L), Mean \pm SD	Singh Index Grade	Testosterone (nmol/L), Mean \pm SD
Normal	No osteoporosis	Normal bone density	18.5 \pm 4.2	VI	19.0 \pm 4.1
				V	16.3 \pm 3.9
Osteopenia	Pre-osteoporosis	Moderate decrease in bone density	14.2 \pm 3.8	IV	13.8 \pm 3.6
Grade I osteoporosis	Early osteoporosis	Initial significant decrease	11.6 \pm 3.5	III	11.2 \pm 3.1
Grade II osteoporosis	Moderate osteoporosis	Marked decrease in bone density	9.8 \pm 2.9	II	9.1 \pm 2.8
Grade III osteoporosis	Severe osteoporosis	Pronounced morphological and structural changes	7.9 \pm 2.6	I	7.5 \pm 2.4

ism is essential for preventing osteoporotic fractures in aging men.

Accurate diagnosis and screening of osteoporosis are essential for timely intervention. The current gold standard for measuring bone mineral density is dual-energy X-ray absorptiometry (DXA). However, DXA is expensive, requires specialized equipment, and is often unavailable in resource-limited or rural healthcare settings. This necessitates alternative, cost-effective screening methods. The proximal femur contains trabecular bone arranged in intersecting arches, which are closely related to its weight-bearing function, as mechanical load is transmitted from the femoral head to the shaft through this trabecular architecture [Osterhoff et al., 2016].

In 1970, Singh and colleagues introduced a morphological classification of trabecular patterns at the proximal femur as a radiographic index of osteoporosis. The Singh Index is an affordable, accessible, and straightforward method for assessing bone density at fracture-prone sites using standard pelvic radiographs. By evaluating the disappearance of specific trabecular groups, clinicians can estimate the degree of bone loss. However, this method has been criticized due to inter-observer variability, and the boundaries between categories may sometimes be subjective [Kanakaris & Lasanianos, 2015; Liu et al., 2017]. Despite these limitations, in settings where advanced densitometry is unavailable, the Singh Index remains a clinically useful triage tool.

Given the critical role of androgens in male bone health and the practical utility of radiographic indices in routine clinical practice, further in-

vestigation is warranted. The present study aimed to investigate the relationship between serum testosterone levels and the severity of osteoporosis assessed by the Singh Index in older men.

MATERIAL AND METHODS

This cross-sectional study was conducted at Dr. Wahidin Sudirohusodo General Hospital, Makassar, Indonesia, from December 2023 to November 2024. The study population comprised men aged >50 years. The institutional ethics committee approved the protocol (No: UH21090579). The inclusion criteria were men aged >50 years. The exclusion criteria included a history of chronic diseases affecting bone metabolism, prior pelvic fracture due to trauma, and treatment with glucocorticoids or anticonvulsant drugs for >6 months.

Singh Index grades: The Singh Index is divided into six grades ranging from 1 (severe osteoporosis) to 6 (normal bone density) [Kanakaris & Lasanianos, 2015; Liu et al., 2017].

Anteroposterior pelvic X-ray: Plain radiographs of the anteroposterior pelvis were obtained using a Multix Select DR system (Siemens Healthineers, Germany). Imaging was performed in the supine position with both legs extended and 15° internal rotation. The central beam was focused on the pubic symphysis with a voltage of 60–70 kVp, exposure time of 1 s, and source-to-image distance of 1 m. Images were evaluated for quality, and the proximal femoral trabecular pattern was assessed according to the Singh Index [Julka et al., 2012; Liu et al., 2017].

Measurement of serum testosterone levels: Serum testosterone levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit (VIDAS

reagent; bioMérieux SA, Marcy-l'Étoile, France; catalog No. 1007817140). Men were classified as testosterone deficient if levels were <12 nmol/L, while normal or borderline levels ranged from 12–40 nmol/L ($\sim >200$ ng/dL) [Watts et al., 2012].

Statistical analysis: Data were analyzed using SPSS version 20. Descriptive statistics were presented as frequencies and percentages. The Spearman correlation test was used to assess the relationship between serum testosterone levels (continuous/ordinal) and Singh Index grades (ordinal). A p -value ≤ 0.05 was considered statistically significant.

RESULTS

This study aimed to determine serum testosterone levels in elderly men, assess osteoporosis grading using the Singh Index, and evaluate the association between testosterone levels and osteoporosis severity. This cross-sectional study was conducted at Wahidin Sudirohusodo hospital, Makassar, Indonesia, from December 2023 to November 2024 onwards.

Table 4 presents the demographic and clinical distribution of serum testosterone levels and osteoporosis severity according to the Singh Index.

The mean testosterone level in the study population was 117.88 ± 110.22 ng/dL. As shown in Table 4, testosterone levels >200 ng/dL were observed in 17 participants (31.5%), while ≤ 200 ng/dL was observed in 37 participants (68.5%).

The results of osteoporosis classification in elderly men according to different grades of the Singh index are presented in Table 5.

The data shown in Table 5 indicate that, in the classification of osteoporosis in elderly men, the most common finding was Grade 3 according to

TABLE 4.

Association of low and borderline testosterone levels with Singh Index grades among elderly men in Indonesia

Variable	Number (%)
Testosterone level (ng/dl)	
> 200	17 (31.5%)
≤ 200	37 (68.5%)
Osteoporosis Singh Index grade	
Heavy	4 (7%)
Moderate	11 (20%)
Definitive	14 (26%)

TABLE 5.

Distribution of patients with osteoporosis in Indonesia according to Singh Index grades

Singh Index score	Distribution according to Singh Index grades		P-value
	Osteoporosis grading	n %	
I	Severe	4 7	2.43 ± 1.62
II	Moderately advanced	11 20	
III	Definitive	14 26	
IV	Transition between normal bone and osteoporosis	7 13	
V	Early stage	7 13	
VI	Normal	11 20	

the Singh index (i.e., confirmed osteoporosis), which was identified in 14 patients (26%).

The mean serum testosterone level was 117.88 ± 110.22 ng/dL. The most common osteoporosis grade was Singh Index Grade 3 (26%). A statistically significant correlation was observed between serum testosterone levels and Singh Index grade ($p < 0.001$). The Spearman correlation analysis demonstrated a strong positive association between testosterone levels and Singh Index grade ($r = 0.942$, $p < 0.001$) in 54 elderly men [Alam A., 2022].

DISCUSSION

In the present study, among older men, the highest prevalence was observed for Singh Index grade 3 (definitive osteoporosis), recorded in 14 patients (26%), whereas the lowest prevalence was observed for Singh Index grade 1 (severe osteoporosis), recorded in four patients (7%). Singh Index grade 2 (moderately advanced osteoporosis) was observed in 11 patients (20%), grade 4 (transition between normal bone and osteoporosis) in seven patients (13%), grade 5 (early-stage osteoporosis) in seven patients (13%), and grade 6 (normal bone) in 11 patients (20%). The Singh Index is an affordable and straightforward method for assessing trabecular bone density at the proximal femur.

The Singh Index has been widely applied for osteoporosis screening and assessment in the literature; however, its diagnostic performance remains controversial. For instance, Shankar et al. reported no significant agreement in Singh Index grading when assessed using kappa statistics, sug-

gesting limited reliability in determining osteoporosis severity [Shankar, 2013]. In contrast, Julka et al. demonstrated significantly lower Singh Index scores in patients with femoral neck fractures compared to age-matched controls ($p < 0.05$), supporting its potential clinical utility [Julka et al., 2012; Liu et al., 2017].

Another study involving 72 patients reported no significant correlation between Singh Index grading and hip bone mineral density ($p = 0.14$). Although the Singh Index demonstrated high sensitivity (96%), its specificity was very low (2%). Compared with dual-energy X-ray absorptiometry (DXA), it showed a positive predictive value of 38% and a negative predictive value of 50%. However, a significant inverse relationship was observed between bone mineral density and age, indicating progressive bone loss with aging [Salamat et al., 2010].

In the present study, 17 patients (31.5%) had serum testosterone levels >200 ng/dL, while 37 patients (68.5%) had levels ≤ 200 ng/dL. Testosterone deficiency is generally defined as serum levels <12 nmol/L ($\sim <350$ ng/dL depending on assay calibration). Testosterone replacement therapy is recommended in selected hypogonadal men at high risk of fracture, according to endocrine society guidelines [Watts et al., 2012].

The analysis demonstrated a statistically significant association ($p < 0.05$) between serum testosterone levels and osteoporosis severity according to the Singh Index. Similarly, Julka et al. reported significant differences in Singh Index scores between fracture patients and controls, supporting its potential role in fracture risk assessment [Julka et al., 2012]. Additionally, Singh Index grades below 4 have been associated with increased risk of femoral neck fractures, particularly grades 1 and 2. The index has also been proposed as a tool for identifying patients who may benefit from prophylactic hip interventions in high-risk populations [Patel & Murphy, 2006].

Karabulut et al. demonstrated a significant positive correlation between Singh Index grades and bone mineral density in postmenopausal women without prior hip fractures, indicating that higher Singh Index grades reflect better bone quality [Karabulut et al., 2010].

Large cohort studies have shown inconsistent associations between testosterone levels and fracture risk. The Concord Health and Ageing in Men Project (958 men aged >70 years) found no association between testosterone levels and fracture risk but identified a significant relationship with hip bone mineral density [Hsu et al., 2016; Shigehara et al., 2021]. Similarly, the Longitudinal Aging Study Amsterdam (623 men aged >55 years) reported a significant association between testosterone levels and hip bone mineral density over follow-up [Kuchuk et al., 2007]. In contrast, larger population-based studies such as the Osteoporotic Fractures in Men Study (USA, $n = 1,436$) and Hong Kong Osteoporotic Fractures in Men Study ($n = 1,498$) found no significant association between testosterone levels and hip bone mineral density [Golds et al., 2017].

Liu et al. evaluated the combination of the Singh Index and the Osteoporosis Assessment Tool for Asians in patients with type 2 diabetes mellitus and reported significant differences in bone mineral density across anatomical sites between fracture and non-fracture groups. They recommended this combined approach as an alternative screening method in resource-limited settings [Liu et al., 2017].

Testosterone exerts both anabolic and androgenic effects on bone metabolism, promoting bone formation through androgen receptor activation in osteoblasts and indirectly via aromatization to estrogen, which inhibits bone resorption [Mohamad et al., 2016; Chen et al., 2019; Zhang et al., 2022]. Therefore, radiographic tools such as the Singh Index may provide a cost-effective alternative for osteoporosis screening in settings where DXA is not available [Liu et al., 2017].

In the present study, a statistically significant relationship ($p < 0.05$) was observed between serum testosterone levels and osteoporosis severity according to Singh Index grading in older men. These findings suggest that testosterone assessment may have potential value in identifying individuals at risk of osteoporosis.

CONCLUSIONS

The present study demonstrated that higher Singh Index grades were associated with lower

prevalence of severe osteoporosis, with Grade 3 being the most frequently observed category among older men. This suggests that the Singh Index may be a useful preliminary screening tool for assessing osteoporosis severity.

A significant association was also observed be-

tween decreased serum testosterone levels and higher severity of osteoporosis according to Singh Index grading. These findings support the potential role of combined hormonal and radiographic assessment in osteoporosis screening among elderly men.

REFERENCES

1. Aggarwal, V., Muthukrishnan, J., Manrai, M., Chauhan, P., & Vasdev, V. (2023). The prevalence of osteoporosis and its association with serum testosterone and serum vitamin D in the elderly male population: A cross-sectional study. *Medical journal, Armed Forces India*, 79(2), 189–193. <https://doi.org/10.1016/j.mjafi.2021.03.011>
2. Alam AR (2022) [The Relationship Between Serum Testosterone Levels And Osteoporosis (Singh Index) In Elderly Men] [Print in Indonesian], requirements for the Specialist Degree in Surgery Makassar, Indonesia
3. APTRM, (2001). Advisory Panel on Testosterone Replacement in Men (2001). Report of National Institute on Aging Advisory Panel on Testosterone Replacement in Men. *The Journal of clinical endocrinology and metabolism*, 86(10), 4611–4614. <https://doi.org/10.1210/jcem.86.10.7942>
4. Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., et al., (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. *The Journal of clinical endocrinology and metabolism*, 103(5), 1715–1744. <https://doi.org/10.1210/jc.2018-00229>
5. Binkley N., Adler R., Bilezikian J.P. (2014). Osteoporosis Diagnosis in Men: The T-Score Controversy Revisited. *Current Osteoporosis Reports*, 12(4), 403–409. <https://doi.org/10.1007/s11914-014-0242-z>
6. Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A. et al., (2020). American Association Of Clinical Endocrinologists/American College Of Endocrinology Clinical Practice Guidelines For The Diagnosis And Treatment Of Postmenopausal Osteoporosis-2020 Update. *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*, 26(Suppl 1), 1–46. <https://doi.org/10.4158/GL-2020-0524SUPPL>
7. Chen J.-F., Lin P.-W., Tsai Y.-R., Yang Y.-C., Kang H.-Y. (2019). Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy. *Cells*, 8(11), 1318. <https://doi.org/10.3390/cells8111318>
8. Fink, H. A., Ewing, S. K., Ensrud, K. E., Barrett-Connor, E., Taylor, B. C., et al., (2006). Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. *The Journal of clinical endocrinology and metabolism*, 91(10), 3908–3915. <https://doi.org/10.1210/jc.2006-0173>
9. Foroutan B. (2024). Osteoporosis Etiology, Epidemiology, Diagnosis, Diet, and Treatment: A Narrative Review. *OBM Geriatrics*, 08(02), 1–60. <https://doi.org/10.21926/obm.geriatr.2402277>
10. Golds G., Houdek D., Arnason T. (2017). Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health. *International Journal of Endocrinology*, 2017, 1–15. <https://doi.org/10.1155/2017/4602129>
11. Hsu B., Seibel M.J., Cumming R.G., Blyth F.M., Naganathan V., Bleicher K., Le Couteur D.G., Waite L.M., Handelsman D.J. (2016). Progressive Temporal Change in Serum SHBG, But Not in Serum Testosterone or Estradiol, Is Associated With Bone Loss and Incident Fractures in Older Men: The Concord Health and Ageing in Men Project. *Journal of Bone and Mineral Research*, 31(12), 2115–2122. <https://doi.org/10.1002/jbmr.2891>
12. Julka A., Shrivastava S., Pandey R., Bhargav P., Ajmera A. (2012). To Evaluate the Utility

- of Singh Index as an Indicator of Osteoporosis and a Predictor of Fracture Neck Femur. *Journal of Anatomical Society of India*, 61(2), 192–198. [https://doi.org/10.1016/S0003-2778\(12\)80033-1](https://doi.org/10.1016/S0003-2778(12)80033-1)
13. *Kanakaris N.K., Lasanianos N.G. (2015)*. Singh Index for Osteoporosis. *Trauma and Orthopaedic Classifications*, 405–407. Springer London. https://doi.org/10.1007/978-1-4471-6572-9_111
 14. *Kanis, J. A., Cooper, C., Rizzoli, R., Reginster, J. Y., ESCEO, IOF (2019)*. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*, 30(1), 3–44. <https://doi.org/10.1007/s00198-018-4704-5>
 15. *Karabulut Ö., Tuncer M.C., Karabulut Z., Hatipoğlu E.S., Nazaroğlu H., Akkuş Z. (2010)*. Evaluation of the Singh index and femur geometry in osteoporotic women. *Central European Journal of Medicine*, 5(5), 601–610. <https://doi.org/10.2478/s11536-010-0027-3>
 16. *Kaufman J.-M., Reginster J.-Y., Boonen S., Brandi M.L., Cooper C., Dere W., et al., (2013)*. Treatment of osteoporosis in men. *Bone*, 53(1), 134–144. <https://doi.org/10.1016/j.bone.2012.11.018>
 17. *Kuchuk N.O., van Schoor N.M., Pluijm S.M.F., Smit J.H., de Ronde W., Lips P. (2007)*. The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women. *Clinical Endocrinology*, 67(2), 295–303. <https://doi.org/10.1111/j.1365-2265.2007.02905.x>
 18. *Liu Z., Gao H., Bai X., Zhao L., Li Y., Wang B. (2017)*. Evaluation of Singh Index and Osteoporosis Self-Assessment Tool for Asians as risk assessment tools of hip fracture in patients with type 2 diabetes mellitus. *Journal of Orthopaedic Surgery and Research*, 12(1), 37. <https://doi.org/10.1186/s13018-017-0539-7>
 19. *Mohamad N.-V., Soelaiman I.-N., Chin K.-Y. (2016)*. A concise review of testosterone and bone health. *Clinical Interventions in Aging*, 11, 1317–1324. <https://doi.org/10.2147/CIA.S115472>
 20. *Osterhoff G., Morgan E.F., Shefelbine S.J., Karim L., McNamara L.M., Augat P. (2016)*. Bone mechanical properties and changes with osteoporosis. *Injury*, 47, S11–S20. [https://doi.org/10.1016/S0020-1383\(16\)47003-8](https://doi.org/10.1016/S0020-1383(16)47003-8)
 21. *Patel S.H., Murphy K.P. (2006)*. Fractures of the proximal femur: Correlates of radiological evidence of osteoporosis. *Skeletal Radiology*, 35(4), 202–211. <https://doi.org/10.1007/s00256-005-0043-3>
 22. *Salamat M.R., Rostampour N., Zofaghari S.J., Hoseyni-Panah H., Javdan M. (2010)*. Comparison of Singh index accuracy and dual energy X-ray absorptiometry bone mineral density measurement for evaluating osteoporosis. *Iranian Journal of Radiation Research*, 8(2), 123–128.
 23. *Shankar V.V. (2013)*. A Radiological Study on the Trabecular Pattern in the Upper End of the Femur in Post-Menopausal Women. *Journal of Clinical and Diagnostic Research*, 7(12), 2777–2779. <https://doi.org/10.7860/JCDR/2013/6984.3752>
 24. *Shigehara K., Izumi K., Kadono Y., Mizokami A. (2021)*. Testosterone and Bone Health in Men: A Narrative Review. *Journal of Clinical Medicine*, 10(3), 530. <https://doi.org/10.3390/jcm10030530>
 25. *Sozen T., Ozisik L., Calik Basaran N. (2017)*. An overview and management of osteoporosis. *European Journal of Rheumatology*, 4(1), 46–56. <https://doi.org/10.5152/eur-jrheum.2016.048>
 26. *Watts N.B., Adler R.A., Bilezikian J.P., Drake M.T., Eastell R., Orwoll E.S., Finkelstein J.S. (2012)*. Osteoporosis in men: An Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*, 97(6), 1802–1822. <https://doi.org/10.1210/jc.2011-3045>
 27. *Zhang H., Ma K., Li R.-M., Li J.-N., Gao S.-F., Ma L.-N. (2022)*. Association between testosterone levels and bone mineral density in females aged 40–60 years from NHANES 2011–2016. *Scientific Reports*, 12(1), 16426. <https://doi.org/10.1038/s41598-022-20869-3>



CONTENTS

4. **ZILFYAN A.V., AVAGYAN S.A., MURADYAN A.A.**
HOW EFFECTIVE IS OUR “UNIVERSAL” RECEPTOR SYSTEM?
20. **BARKHUDARYAN A. L., CHILINGARYAN A. L., TUNYAN L. G.**
THE CURRENT STATE OF KNOWLEDGE ON THE MANAGEMENT OF ISCHEMIC HEART DISEASE IN PATIENTS WITH CANCER
34. **HARUTYUNYAN A. A., CHOPIKYAN A. S., GYULAZYAN N. M., MKHITARIAN M. H., SARGSYAN L. G., TADEVOSYAN A. E.**
FUNCTIONING OF MEDICAL INSTITUTIONS IN YEREVAN AND THE REGIONS OF ARMENIA DURING THE COVID-19 PANDEMIC
41. **TADEVOSYAN A. E., GYULAZYAN N. M., GHAZARYAN A.G., HOVHANNISYAN A.H., KARAPETYAN A.G., CHOPIKYAN A.S., HARUTYUNYAN A.A., MANUKYAN R.G., SARGSYAN L.G., MURADYAN A.A.**
SIGNIFICANCE OF SARS-COV-2 PCR POSITIVE AND NEGATIVE RESULTS IN THE CLINICAL COURSE AND LABORATORY PARAMETERS OF COVID-19
50. **AMR M.A.M., EL-SAYED MOHAMMAD H., ZAKI N.F., SOLIMAN A.A.A., AROCKIASAMY A.P.R.**
COGNITIVE PROFILES OF CHILDREN WITH ENCOPRESIS: INSIGHTS FROM THE STANFORD–BINET TEST
59. **AJDARI A., GHAEMI M.R., HOOSHMAND H., RADVAR M.**
EPIDEMIOLOGICAL CHARACTERISTICS AND COMORBIDITIES IN CHILDREN WITH ASTHMA
67. **ALAM A.R., MUSTARI M.N., LATIEF J., RASJAD C., BAUSAT A., ZAINUDDIN A.A., PRIHANTONO P., FARUK M.**
RELATIONSHIP BETWEEN SERUM TESTOSTERONE AND OSTEOPOROSIS IN OLDER MEN: A CROSS-SECTIONAL STUDY
74. **HOVHANNISYAN A.H., MANUKYAN S.G., MKHITARYAN S.L., KHACHATRYAN S.H., GYULAZYAN N.M., ASOYAN V.A.**
MULTIFOCAL OSTEOARTICULAR BRUCELLOSIS: A RARE CASE OF SPONDYLO-DISCITIS, VERTEBRAL ABSCESS, AND KNEE ARTHRITIS
81. **KREICBERGA I., REZEBERGA D., MISOVA A., VARDANYAN R., ARBUZOV G., TĒRVIDS T.**
COMPARISON OF RADIANT HEAT FLUX FROM A LARGE-SURFACE AND CONVENTIONAL NEONATAL WARMER USING STANDARDIZED BLACK BODY PLACEMENT
90. **KREICBERGA I., REZEBERGA D., MISOVA A., VARDANYAN R., ARBUZOV G., TĒRVIDS T.**
COMPARISON OF THERMAL CONDITIONS UNDER A COMMERCIAL NEONATAL RADIANT WARMER AND A NEWLY DEVELOPED LARGE-SURFACE RADIANT WARMER
102. **TANASHYAN M.M., RASKURAZHEV A.A., KUZNETSOVA P.I., SHABALINA A.A., PIRADOV M.A.**
ASPIRIN RESISTANCE IN PATIENTS WITH CEREBRAL ATHEROSCLEROSIS: POSSIBLE ROLE OF MICRORNAs
111. **KAKURINA G.V., SEREDA E.E., CHEREMISINA O.V., SIDENKO E.A., YUNUSOVA N.V., KORSHUNOV D.A., KONDAKOVA I.V., CHOYNZONOV E.L.**
THE RELATIONSHIP BETWEEN THE EXPRESSION ACTIVITY OF GENES ENCODING VIMENTIN AND ACTIN-BINDING PROTEINS IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WITH LYMPHOGENOUS METASTASIS.
119. **ALUBAIDI G.T. (LETTER TO THE EDITOR)**
NIPAH VIRUS PROPOSED VACCINES: ARE WE PREPARED FOR THE EXPECTED PANDEMIC?



The Journal is founded by
Yerevan State Medical
University after M. Heratsi.

Rector of YSMU

Armen A. *MURADYAN*

Address for correspondence:

Yerevan State Medical University
2 Koryun Street, Yerevan 0025,
Republic of Armenia

Phones:

(+37410) 582532 YSMU

(+37493) 588697 Editor-in-Chief

Fax: (+37410) 582532

E-mail: namj.ysmu@gmail.com, ysmiu@mail.ru

URL: <http://www.ysmu.am>

Our journal is registered in the databases of Scopus, EBSCO and Thomson Reuters (in the registration process)



SCOPUS



EBSCO



THE GUFO

Print in "Monoprint" LLC
Director: Armen Armenakyan
Andraniks St., 96/8 Bulding
Yerevan, 0064, Armenia
Phone: (+37491) 40 25 86
E-mail: monoprint1@mail.ru

TheGufo is an online database platform designed to help researchers publish and share their scientific work on a global scale. Our company was founded to address the need for affordable and user-friendly platform that removes many of the barriers traditionally imposed by the publishing industry.

All scientific work published through TheGufo complies with Creative Commons 4.0 and other recognized standards to ensure authenticity, proper referencing, and academic integrity. Each submission undergoes a detailed peer-review process prior to publication.

Our mission is to provide researchers worldwide with a professional, accessible, and cost-effective platform to share both new and existing work with their peers. To further encourage participation, we also offer special promotional programs for academic institutions.

*Dear reader, to access our website, please follow the link below
<https://thegufo.com/> https://*

Editor-in-Chief

Arto V. *ZILFYAN* (Yerevan, Armenia)

Deputy Editors

Hovhannes M. *MANVELYAN* (Yerevan, Armenia)

Hamayak S. *SISAKYAN* (Yerevan, Armenia)

Executive Secretary

Stepan A. *AVAGYAN* (Yerevan, Armenia)

Editorial Board

Armen A. *MURADYAN* (Yerevan, Armenia)

Drastamat N. *KHUDAVERDYAN* (Yerevan, Armenia)

Suren A. *STEPANYAN* (Yerevan, Armenia)

Foregin Members of the Editorial Board

Waleed *GHANIMA* (Oslo, Norway)

Carsten N. *Gutt* (Memmingen, GERMAY)

Ming-Hua *ZHENG* (Wenzhou, China)

Coordinating Editor (for this number)

Farzad *KARIMPOUR* (Yasuj, IR Iran)

Editorial Advisory Council

Vahe Yu. *AZATYAN* (Yerevan, Armenia)

Ara S. *BABLOYAN* (Yerevan, Armenia)

Ines *BANJARI* (Osijek, Croatia)

Azat A. *ENGIBARYAN* (Yerevan, Armenia)

Mahdi *ESMAEILZADEH* (Mashhad, IR Iran)

Ruben V. *FANARJYAN* (Yerevan, Armenia)

Gabriele *FRAGASSO* (Milano, Italy)

Samvel G. *GALSTYAN* (Yerevan, Armenia)

Armen Dz. *HAMBARDZUMYAN* (Yerevan, Armenia)

Airazat M. *KAZARYAN* (Oslo, Norway)

Seyran P. *KOCHARYAN* (Yerevan, Armenia)

Levon M. *MKRTCHYAN* (Yerevan, Armenia)

Ashot M. *MKRTUMYAN* (MoscowRussia)

Mariam R *MOVSIYAN* (Gumri, Armenia)

Mikhail Z. *NARIMANYAN* (Yerevan, Armenia)

Sevak *SHAHBAZYAN* (Yerevan, Armenia)

Arthur K. *SHUKURYAN* (Yerevan, Armenia)

Gevorg N. *TAMAMYAN* (Yerevan, Armenia)

Marine M. *TANASHYAN* (Moscow, Russia)

Hakob V. *TOPCHYAN* (Yerevan, Armenia)

Alexander *WOODMAN* (London, England)

Konstantin B. *YENKOYAN* (Yerevan, Armenia)

Yumei *NIU* (Harbin, China)

Peijun *WANG* (Harbin, Chine)